XGene Regulatory Intelligence Platform
Connect enforcement signals to quality systems, services, expert commentary, and implementation resources.
Cell therapy CMC packages fail at CBER not because the science is wrong, but because the regulatory architecture is borrowed from the wrong framework.
View details →
The most consequential CMC decision in an autologous cell therapy program is not the manufacturing process — it is how you define, characterize, and control the starting material that arrives in your facility before
View details → A CAR-T manufacturing process description is the only place in a CMC package where a reviewer can see whether you understand that every step modifies the drug. Most process descriptions treat it like a
View details → Potency for a cell therapy product is not a release test. It is the primary regulatory evidence that manufacturing produced cells that can do what the label claims. CBER treats it accordingly — and
View details → The specifications for a cell therapy lot are the single document that determines what goes into a patient. In personalized medicine manufacturing, they also determine whether you can treat the patient at all.
View details →
In autologous cell therapy, chain-of-identity failure is not a quality event — it is a patient safety catastrophe. The CMC section that describes your CoI system is evaluated by CBER with that understanding.
View details → The most technically sophisticated cell therapy can be destroyed between the manufacturing facility and the clinic. Cold chain failures in cell therapy are CMC failures — and CBER evaluates them as such.
View details → Allogeneic cell therapy does what autologous cannot: it makes a single manufacturing batch that can treat hundreds of patients. The CMC infrastructure required to support that model is categorically different.
View details → iPSC-derived cell therapies represent the most ambitious manufacturing challenge in modern medicine. The CMC package required to support a CBER IND for one of these products reflects that ambition — and its complexity.
View details → Tumor-infiltrating lymphocyte and NK cell therapies occupy the frontier of cell therapy CMC. The regulatory expectations are evolving — but CBER's fundamental requirements for potency, identity, and manufacturing consistency are not.
View details → Cell therapy stability studies are not shorter versions of biologics stability programs. They are fundamentally different studies — because cell therapy products degrade through biological processes that conventional stability science was not built to
View details →
Process validation for cell therapy is not impossible — it is just different. The FDA's 2011 guidance applies. But the way you design Stage 1, execute Stage 2, and monitor Stage 3 must reflect
View details → The analytical methods used to characterize and release cell therapy products are unlike any other in pharmaceutical science. Validating them to ICH Q2(R2) requires a cell-therapy-specific strategy that most standard method validation platforms cannot
View details → The QOS for a cell therapy product must summarize a drug that is, by definition, incompletely characterized. The way you handle that reality in Module 2.3 determines whether CBER trusts your entire CMC package.
View details → The cell therapy programs that reach BLA submission on schedule are not the ones that moved fastest in Phase 1. They are the ones that invested in CMC infrastructure while moving through Phase 1.
View details → A cell therapy CMC package built for CBER will satisfy many EMA requirements — and fail specific ones. Discovering which ones at pre-submission costs less than discovering them at Day 180 of a CAT
View details → A cell therapy BLA without a facility that passes inspection is a submission, not an approval. Understanding what CBER inspectors evaluate before you build or validate your facility is the only way to avoid
View details → The most successful cell therapy programs treat BLA approval not as the end of CMC work, but as the beginning of the manufacturing lifecycle where every change requires a regulatory strategy.
View details →